Melanotan II: what the published research shows

Melanotan II (MT-II), also referred to in the literature as melanotan-II and by the shorthand MT-II, is a synthetic peptide analog belonging to the melanocortin hormone family. It is an unlicensed compound and is described in published case reports as a cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) [1]. The evidence block for this page does not supply a sequence, molecular formula, or molecular weight for Melanotan II, so none are stated here. The work summarised below centres on the melanocortin receptor family, a group of Class A G protein-coupled receptors (GPCRs) with five subtypes (MC1R through MC5R) that are expressed both centrally and peripherally and that have established roles in pigmentation, steroidogenesis, and energy homeostasis [6].

Melanotan II is reported to act primarily by activating melanocortin 1 receptors on melanocytes, stimulating eumelanin production and producing skin pigmentation independent of sun exposure [1]. That receptor-level description is the anchor for the studies and case reports collected here.

Research Studies

Melanotan II and melanocortin 1 receptor activation in melanocytes

The mechanistic account given in the clinical case literature is that Melanotan II activates melanocortin 1 receptors located on melanocytes, which drives eumelanin production and results in pigmentation that does not depend on ultraviolet exposure [1]. This places the compound within the same receptor family discussed in the melanocortin tool-compound literature, where the five melanocortin receptor subtypes are treated as a centrally and peripherally expressed Class A GPCR family with roles spanning pigmentation, steroidogenesis, and energy homeostasis [6]. The tool-compound review notes that several physiological roles of this receptor family remain to be fully characterised [6].

Melanotan II and oral mucosa in a self-administered injection case

A case report followed a patient for three months after the patient self-administered Melanotan II injections over a period of 64 days with the goal of achieving a deeper tanning effect [1]. On initial intraoral examination, brown pigmentation was observed [1]. The report frames Melanotan II as an unlicensed synthetic peptide analog of the melanocortin hormone family whose use is associated with a range of potential adverse effects, and it notes that the compound remains unregulated despite promotion on social media [1]. This is a single-patient observational report; it does not establish incidence or causation across a population.

Melanotan II and repigmentation in stable nonsegmental vitiligo

A registered interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo [2]. The record identifies the study as interventional and randomized, and the population as adults with stable nonsegmental vitiligo [2]. No results are reported in the evidence block, so no efficacy or safety outcome is stated here.

Melanotan II and oral mucosal findings in a nasal spray case

A published case reports a 22-year-old female who developed a mass in the anterior maxilla after using Melanotan II, described as a nasal spray containing a synthetic analogue of melanocyte-stimulating hormone, for tanning purposes [3]. The report notes that Melanotan II is unlicensed and that its sale is illegal in the United Kingdom [3]. This is a single case in one patient and does not establish a rate of occurrence in any broader population.

Melanotan II and antidepressant-like effects in a rat chronic stress model

A study examined antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II in male rats using a model of chronic unpredictable stress [4]. The paper situates this work against the limitations of current antidepressant therapy and the role of stressful events and hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of depression, and it reports that HPA axis activity is selectively affected [4]. This finding is animal-only, in male rats, and does not translate directly to human outcomes.

Melanotan II and analytical identification of 'Barbie drug' samples

A laboratory identification study analysed submitted samples, including two vials with a pharmaceutical appearance, using HPLC-DAD, UHPLC-TOF-MS, and/or UPLC-MS-MS, with the stated aim of describing the unique characteristics observed during analysis of the powder contained in the vial [5]. The work is presented as an identification exercise on submitted samples rather than a controlled study of an effect [5]. It is included here because it documents analytical approaches applied to materials encountered in this category.

Melanotan II and melanocortin receptor tool-compound context

The melanocortin receptor family is described as a centrally and peripherally expressed group of Class A GPCRs with five subtypes, excluding the melanocortin-2 receptor (MC2R) from the generalisation in the source text [6]. The review frames these receptors as having physiological roles in pigmentation, steroidogenesis, and energy homeostasis, alongside roles yet to be fully characterised [6]. Melanotan II appears in the wider literature as a melanocortin-family synthetic peptide analog [1], which is the context in which receptor-level work on this compound is typically discussed.

Melanotan II and reported adverse events across case material

Across the case material summarised above, reported findings include brown pigmentation of the oral mucosa following self-administered injections over 64 days [1] and a mass in the anterior maxilla in a 22-year-old female following nasal spray use [3]. The injection case report states that Melanotan II use is associated with a range of potential adverse effects and that the compound remains unregulated [1]. The nasal spray case report states that Melanotan II is unlicensed and that its sale is illegal in the United Kingdom [3]. These are individual case reports; they describe what was observed in specific patients and do not provide incidence figures.

Melanotan II and the limits of the current evidence base

The evidence collected here is heterogeneous. It includes a three-month single-patient follow-up [1], a registered Phase 2 trial record without reported results [2], two further single-patient case reports [3][5], an animal study in male rats [4], and a receptor-family review [6]. Where findings come from animal models, they are animal-only; where they come from single case reports, they describe one patient. The evidence block does not supply human dosing information, pharmacokinetic parameters, or efficacy conclusions, and none are asserted here.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report — https://europepmc.org/article/PMC/PMC12942211
• [2] Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo — https://clinicaltrials.gov/study/NCT07437560
• [3] Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? — https://pubmed.ncbi.nlm.nih.gov/40210573/
• [4] Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress — https://pubmed.ncbi.nlm.nih.gov/39442746/
• [5] Barbie drug identification: Not a child's play — https://pubmed.ncbi.nlm.nih.gov/39302005/
• [6] Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs) — https://europepmc.org/article/PMC/PMC11406693